

- **Name:** Sook-hee Hong
 - **Current Position & Affiliation:** Professor in Division of Oncology
Seoul St. Mary's Hospital, The Catholic University of Korea, Korea
 - **Country:** Republic of Korea
-

• **Educational Background:**

- M.S., Medicine, 2000, Catholic University Medical College, Seoul, Korea
- Ph. D., Internal Medicine, 2013, Catholic University Medical College, Seoul, Korea

• **Professional Experience:**

- March.2007- Feb.2010 Instructor in Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
- March.2010- Mar. 2014 Assistant Professor in Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
- April 2014 – Mar.2019 Associated Professor in Division of Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Korea
- April 2019 – present Professor in Division of Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Korea
- Feb 2015 - Feb 2016 Visiting Scholar, Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard University

• **Professional Organizations:**

- Korean Medical Association
- The Korean Association of Internal Medicine
- Korea cancer study group
- Korean Society of Medical Oncology

• **Main Scientific Publications:**

1. How to start niraparib in real-world Asian ovarian cancer patients? Hong SH. J Gynecol Oncol. 2021 Mar;32(2):e36.
2. Hippo pathway as another oncogenic mediator to promote immune evasion by PD-L1 signaling. Hong SH. J Thorac Dis. 2019 Mar;11(Suppl 3):S318-S321.
3. The Prognostic Value of Sex-Determining Region Y-Box 2 and CD8+ Tumor-Infiltrating Lymphocytes in Limited-Stage Small-Cell Lung Cancer. Lee J, Jung YY, Lee JH, Hong M, Hwang HW, Hong SA, Hong SH. Oncology. 2021;99(8):528-538.
4. Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07. Kim M, Keam B, Ock CY, Kim SH, Kim YJ, Lim SM, Kim JS, Kim TM, Hong SH, Ahn MS, Shin SH, Kang EJ, Kim DW, Im SW, Kim JI, Lee JS, Kim JH, Heo DS. Thorac Cancer. 2020 Dec;11(12):3482-3489.
5. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving

- immunotherapy. Kim SR, Chun SH, Kim JR, Kim SY, Seo JY, Jung CK, Gil BM, Kim JO, Ko YH, Woo IS, Shim BY, Hong SH, Kang JH. *BMC Cancer*. 2021 Jan 5;21(1):19.
6. Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer. Kim JO, Shin JY, Kim SR, Shin KS, Kim J, Kim MY, Lee MR, Kim Y, Kim M, Hong SH, Kang JH. *Cancers (Basel)*. 2020 Mar 26;12(4):785.
 7. Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea. Lee HY, Hong JH, Byun JH, Kim HJ, Baek SK, Kim JY, Kim KH, Yun J, Kim JA, Park K, Lee HJ, Lee JL, Won YW, Kim IH, Bae WK, Park KH, Sun DS, Lee S, Lee MY, Lee GJ, Hong SH, Jung YH, An HJ. *Cancer Res Treat*. 2020 Jan;52(1):277-283.
 8. Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, Buczkowski KA, Bockorny B, Chen T, Li S, Rhee K, Zhang H, Chen W, Terai H, Tavares T, Leggett AL, Li T, Wang Y, Zhang T, Kim TJ, Hong SH, Poudel-Neupane N, Silkes M, Mudianto T, Tan L, Shimamura T, Meyerson M, Bass AJ, Watanabe H, Gray NS, Young RA, Wong KK, Hammerman PS. *Cancer Discov*. 2018 Jan;8(1):59-73.
 9. Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Park EY, Kim YS, Choi KH, Song JH, Lee HC, Hong SH, Kang JH. *Radiat Oncol J*. 2019 Sep;37(3):166-175. 16.
 10. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. Kim H, Lee JE, Hong SH, Lee MA, Kang JH, Kim IH. *BMC Cancer*. 2019 Nov 12;19(1):1100.
 11. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival. Hong SA, Jang SH, Oh MH, Kim SJ, Kang JH, Hong SH. *Pathol Res Pract*. 2018 Mar;214(3):335-342.
 12. Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program. Hong SH, An HJ, Kim K, Lee SS, Lee YG, Yuh YJ, Park IC, Chae YS, Jang TW, Kang JH. *Oncology*. 2019;96(1):51-58.